辅助中药治疗改善台湾胃癌患者生存:全国回顾性匹配队列研究
该研究基于台湾1997至2010年灾难性疾病患者登记库,纳入年龄≥18岁的胃癌患者,采用1:1频数匹配比较中药使用者与非使用者的死亡风险。结果显示中药使用者调整后死亡风险比显著降低(aHR 0.55,95%CI 0.48-0.62),每年使用中药超过180天者aHR为0.37(95%CI 0.2-0.67),提示辅助中药可能改善胃癌患者总体生存。
要点
- 中药辅助治疗与胃癌患者死亡风险降低相关(aHR 0.55,95%CI 0.48-0.62)。
- 每年使用中药超过180天者死亡风险更低(aHR 0.37,95%CI 0.2-0.67)。
- 常用单味药为白花蛇舌草,常用复方为香砂六君子汤。
核心结论
- 辅助中药治疗可改善台湾胃癌患者的总体生存。
- 需进一步民族药理学研究与临床试验验证其疗效与安全性。
研究设计与样本
- 全国回顾性匹配队列研究,数据来自台湾灾难性疾病患者登记库。
- 纳入1997至2010年诊断时年龄≥18岁的所有胃癌患者。
- 采用1:1频数匹配(按年龄、性别、Charlson合并症评分、治疗和索引年)比较中药使用者与非使用者。
- 中药队列1333例,非中药队列44786例;匹配后各962例新诊断患者进入比较。
主要发现
- 中药使用者死亡风险调整后风险比(aHR)为0.55(95%CI 0.48-0.62)。
- 每年使用中药超过180天者aHR为0.37(95%CI 0.2-0.67)。
- Kaplan-Meier曲线显示中药使用者生存概率更高。
- 年龄>60岁、索引日前Charlson合并症指数≥2、需手术联合化疗或放疗者aHR更高。
- 最常用单味药为白花蛇舌草(Herba Hedyotidis Diffusae),最常用复方为香砂六君子汤。
临床怎么用
- 在胃癌综合治疗中可考虑辅助中药治疗,尤其长期(每年>180天)使用者可能获益更明显。
- 白花蛇舌草与香砂六君子汤是该研究中常用的中药选择。
局限性
- 为回顾性队列研究,可能存在未测量的混杂因素。
- 需进一步民族药理学研究与临床试验验证疗效与安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Many patients with gastric cancer seek traditional medicine consultations in Asian countries. This study aimed to investigate the prescription of Chinese herbal medicine (CHM) and its benefits for the patients with gastric cancer in Taiwan. METHODS: From the Registry for Catastrophic Illness Patients Database, we included all patients with gastric cancer whose age at diagnosis was ≥18 from 1997 to 2010 in Taiwan. We used 1:1 frequency matching by age, sex, Charlson comorbidity score, treatment and index year to compare the CHM users and non-CHM users. We used the Cox regression model to compare the hazard ratios (HR) for the risk of mortality and the Kaplan-Meier curve for the survival time. RESULTS: There was a total of 1333 patients in the CHM-cohort and 44786 patients in the non-CHM cohort. After matching, we compared 962 newly diagnosed CHM users and 962 non-CHM users. Adjusted HRs (aHR) were higher among patients of above 60-year-old group, with a Charlson Comorbidity Index score ≥2 before the index date, and those who need surgery combined with chemotherapy or radiotherapy. CHM users had a lower HR of mortality risk (adjusted HR: 0.55, 95% CI: 0.48-0.62). Compared to the non-CHM users, the aHR among CHM-users is 0.37 (95% CI:0.2-0.67) for those who used CHM more than 180 days annually. The Kaplan-Meier curve revealed that the survival probability was higher for complementary CHM-users. Bai-Hua-She-She-Cao (Herba Hedyotidis Diffusae) was the most commonly used single herb and Xiang-Sha-Liu-Jun-Zi-Tang was the most commonly used herbal formula among CHM prescriptions. CONCLUSIONS: Complementary CHM improves the overall survival among patients with gastric cancer in Taiwan. Further ethnopharmacological investigations and clinical trials are required to validate the efficacy and safety.
引用
- Hung KF, Hsu CP, Chiang JH, et al. Complementary Chinese herbal medicine therapy improves survival of patients with gastric cancer in Taiwan: A nationwide retrospective matched-cohort study. J Ethnopharmacol. 2017. PMID: 28163114. doi:10.1016/j.jep.2017.02.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。